Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)
398.20
-1.90 (-0.47%)
NASDAQ · Last Trade: Nov 6th, 9:48 AM EST
News & Press Releases
Did You Lose Money on Madrigal Pharmaceuticals, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 8.1% Share Price Decline
Investors who suffered losses on Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) investors into whether the Company may have violated the federal securities laws. The investigation comes after a November 3, 2026 disclosure concerning Madrigal Pharmaceuticals, Inc.
By The Law Offices of Howard G. Smith · Via Business Wire · November 6, 2026
Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 6, 2026
Kaplan Fox Alerts Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Possible Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 5, 2026
Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Q2 Beat Yet Shares Slide on Rezdiffra Ramp Worrieschartmill.com
Via Chartmill · July 30, 2026
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Dip Despite Q1 2026 Earnings Beat and 127% Rezdiffra Revenue Growthchartmill.com
Via Chartmill · May 6, 2026
Lost Money on Madrigal Pharmaceuticals, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 8.1% Stock Decline
Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Madrigal Pharmaceuticals, Inc. on November 3, 2026.
By The Law Offices of Frank R. Cruz · Via Business Wire · November 5, 2026
Kaplan Fox & Kilsheimer LLP Encourages Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding Potential Securities Law Violations
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL).
By Kaplan Fox & Kilsheimer, LLP · Via GlobeNewswire · November 5, 2026
Madrigal (MDGL) Q3 2026 Earnings Call Transcriptfool.com
Rezdiffra hits blockbuster status as net income turns positive for first time.
Via The Motley Fool · November 3, 2026
What Madrigal Pharmaceuticals (MDGL) Said on Its Q3 Earnings Callmarketbeat.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported third-quarter 2026 net sales of $431.3 million for its MASH treatment Rezdiffra, up 50% from the prior-year period, as the company said it continued to add patients and expand its prescriber base. Year-to-date net sales reached $1.1 billion, and the co
Via MarketBeat · November 3, 2026
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?fool.com
Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease.
Via The Motley Fool · September 10, 2026
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Offfool.com
Rezdiffra's biggest growth opportunity may still be ahead.
Via The Motley Fool · August 25, 2026
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expandsmarketbeat.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential clinical catalysts.
Speaking at a Canaccord Genuity event, C
Via MarketBeat · August 15, 2026
Madrigal Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported second-quarter 2026 net sales of $364.3 million for Rezdiffra, up 71% from a year earlier, as the company continued to expand the number of patients receiving its treatment for metabolic dysfunction-associated steatohepatitis, or MASH.
The company sai
Via MarketBeat · July 30, 2026
3 Under-the-Radar Stocks to Buy and Holdfool.com
Sometimes, little-known stocks are worth buying.
Via The Motley Fool · July 10, 2026
3 Under-the-Radar Stocks to Buy and Hold for a Decadefool.com
All three could become highly prominent biotech companies within 10 years.
Via The Motley Fool · June 16, 2026
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%fool.com
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.
Via The Motley Fool · May 29, 2026
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million Morefool.com
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.
Via The Motley Fool · May 29, 2026
Arrowhead (ARWR) Q2 2026 Earnings Transcriptfool.com
Arrowhead (ARWR) Q2 2026 Earnings Transcript
Via The Motley Fool · May 8, 2026
Madrigal (MDGL) Q1 2026 Earnings Transcriptfool.com
Madrigal (MDGL) Q1 2026 Earnings Transcript
Via The Motley Fool · May 6, 2026
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlistfool.com
These companies boast significant upside potential.
Via The Motley Fool · April 16, 2026
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Nowfool.com
The next 10 months might be challenging for this biotech.
Via The Motley Fool · March 25, 2026
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Storyfool.com
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
Via The Motley Fool · March 21, 2026
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launchfool.com
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.
Via The Motley Fool · March 21, 2026
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fundfool.com
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.
Via The Motley Fool · March 20, 2026
2 Under-the-Radar Stocks to Buy and Holdfool.com
These biotechs are slowly making a name for themselves.
Via The Motley Fool · March 10, 2026